Conquer Cancer Logo

ADVANCED CLINICAL RESEARCH AWARD (ACRA) FOR DIVERSITY AND INCLUSION

ACRA FOR DIVERSITY AND INCLUSION

The ACRA for Diversity and Inclusion is designed with the primary goal of increasing diversity in the oncology workforce and cancer research.  Awards will be given to mid-career investigators who are members of racial and/or ethnic groups historically underrepresented in academic medicine and wish to conduct original breast cancer research not currently funded..

Funding Available

The ACRA is a three-year grant totaling $450,000 that supports personnel and/or research expenses, and travel to attend the Conquer Cancer Grants and Awards Ceremony at the ASCO Annual Meeting. There is funding for one ACRA for Diversity and Inclusion.

Eligibility for the ACRA for Diversity and Inclusion

Applicants must meet the following criteria to qualify for this ACRA:

  • Identify as a member of a racial/ethnic group historically underrepresented in academic medicine.
  • Be a physician (MD, DO, or international equivalent) who is in the fourth to ninth year of a full-time, primary faculty appointment in a clinical department at an academic medical institution at the time of grant submission.
  • Have completed productive post-doctoral/post fellowship research and demonstrated the ability to undertake independent investigator-initiated clinical research in breast cancer.
  • Be an ASCO Full Member or have submitted a membership application with the grant application.
  • Be able to commit 75% of full-time effort in research (applies to total research, not just the proposed project) during the award period.

Application Instructions

All application materials must be in English and must be submitted through the Application Portal. Paper applications or applications sent by e-mail or fax will not be accepted.

 


ADVANCED CLINICAL RESEARCH AWARD IN IMMUNE CHECKPOINT INHIBITOR THERAPY 

The Advanced Clinical Research Award (ACRA) is designed to support physician-scientists committed to performing original, clinical cancer research in an area not currently funded. This research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects.

 

ACRA IN IMMUNE CHECKPOINT INHIBITOR THERAPY

The ACRA in Immune Checkpoint Inhibitor Therapy is intended to support research to determine successful therapeutic combination regimens to overcome resistance problems associated with immune checkpoint inhibitors. The focus of this award is to understand 1) mechanisms of resistance to immune checkpoint inhibitors, 2) therapeutic approaches of combining immune checkpoint therapy with neoadjuvant strategies, 3) novel drug combination strategies with PD-1 inhibitors.

Funding Available

The ACRA is a three-year grant totaling $450,000 that supports personnel and/or research expenses, and travel to attend the Conquer Cancer Grants and Awards Ceremony at the ASCO Annual Meeting. 

There is funding for one ACRA in Immune Checkpoint Inhibitor Therapy.

Eligibility for the ACRA Immune Checkpoint Inhibitor Therapy

Applicants must meet the following criteria to qualify for this ACRA:

  • Be a physician (MD, DO, or international equivalent) working in any country
  • Be in the fourth to ninth year of a full-time, primary faculty appointment in a clinical department at an academic medical institution at the time of grant submission.
  • Have completed productive post-doctoral/post fellowship research and demonstrated the ability to undertake independent investigator-initiated clinical research.
  • Be an ASCO Full Member or have submitted a membership application with the grant application.
  • Be able to commit 75% of full-time effort in research (applies to total research, not just the proposed project) during the award period.

Application Instructions

All application materials must be in English and must be submitted through the Application Portal. Paper applications or applications sent by e-mail or fax will not be accepted.

Closed

Supporters

               

This list reflects commitments as of May 25, 2021.

This grant receives support that may result in a report to the CMS Open Payments website under the Physician Payments Sunshine Act. The supporting companies are required to report the amount of the grant, the names of physicians who are awarded this grant, and the names of their institutions. This information may appear on the Open Payments websiteFind out more information about the Sunshine Act and CMS Open Payments program.